Group 1 - The core issue involves potential securities fraud claims against Petco Health and Wellness Company, linked to a class action lawsuit regarding misleading statements about its pandemic-related growth and the sustainability of its premium pet food business model [1][2] - Petco's stock price experienced significant declines, including a drop of over 20% on August 24, 2023, following a downward revision of its financial outlook, compounded by leadership changes and ongoing operational challenges [2][3] - The lawsuit highlights that Petco's shift to include "value" pet food brands and multiple executive departures indicated deeper operational weaknesses, leading to increased losses for investors [3] Group 2 - The class period for the lawsuit is defined as January 14, 2021, through June 5, 2025, allowing investors who acquired Petco stock during this timeframe to seek lead plaintiff status by August 29, 2025 [3] - Berger Montague, the firm investigating the claims, has a long history in securities class action litigation, representing investors for over five decades [5]

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and regulatory non-compliance [1][3][4]. Group 1: Legal Investigation - Investors who acquired Hims & Hers securities between April 29, 2025, and June 22, 2025, have until August 25, 2025, to seek appointment as lead plaintiff representative [2]. - The lawsuit claims that Hims & Hers made materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [4]. Group 2: Market Reaction - Following the announcement of the partnership termination, Hims & Hers shares fell by over 34% in intraday trading, indicating significant investor concern over regulatory compliance and reputational risks [3].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against KinderCare Learning Companies, Inc. following a class action lawsuit related to undisclosed safety and compliance failures at its facilities [1][3]. Group 1: Company Overview - KinderCare Learning Companies, Inc. is a national operator of early childhood education centers, headquartered in Portland, Oregon [2]. Group 2: Legal Proceedings - A securities class action lawsuit has been filed on behalf of investors who purchased KinderCare securities between October 6, 2024, and August 12, 2025, including during the Company's initial public offering in October 2024 [1][2]. - Investors have until October 14, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 3: Allegations and Impact - The investigation focuses on allegations that KinderCare failed to disclose incidents of child abuse, neglect, and harm at its centers, leading to significant safety and compliance concerns [3]. - At the time the lawsuit was filed, KinderCare's stock had fallen to approximately $9 per share, representing a loss of about 60% from its IPO value [3].

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating Hims & Hers for possible violations of federal securities laws during the Class Period from April 29, 2025, to June 22, 2025 [1]. - The investigation follows a significant drop in Hims & Hers' stock price, which fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2]. - A complaint has been filed alleging that Hims & Hers made material misstatements and omissions, violating federal securities laws [2]. Group 2: Legal Actions - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other affected investors [3].

Group 1 - The core issue involves securities fraud claims against Spectrum Pharmaceuticals, Inc. related to misleading statements about its Pinnacle Study for the drug poziotinib [1][3] - The class action lawsuit pertains to investors who acquired Spectrum shares between March 17, 2022, and September 22, 2022 [1][2] - Spectrum Pharmaceuticals is primarily focused on oncology treatments [2] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representative in the class action [2] - Following a merger with Assertio Holdings, Inc., Spectrum shares were delisted [3]

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Company Summary - Novo Nordisk A/S, a global pharmaceutical company based in Denmark, has faced a significant stock price decline after announcing a reduction in sales and profit expectations due to various market challenges [1][3]. - The company cited persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® as reasons for the guidance cut [3]. Stock Performance - Following the announcement on July 29, 2025, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative in the class action [2].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. following a class action lawsuit related to the company's performance during a specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit was filed for investors who purchased or acquired Altimmune securities between August 10, 2023, and June 25, 2025 [1][2]. - The lawsuit alleges that Altimmune's IMPACT study failed to achieve statistical significance in its primary endpoint of fibrosis reduction, which was attributed to a higher-than-expected placebo response [3]. - Following the announcement of the study results on June 26, 2025, Altimmune's stock price dropped 53%, from $7.71 per share to $3.61 per share, resulting in significant losses for investors [4]. Group 2: Company Background - Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland [2]. - Berger Montague has a long history in securities class action litigation, having represented individual and institutional investors for over five decades [5].

Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Legal Investigation - Berger Montague is investigating Hims & Hers for potential securities fraud claims, particularly regarding misleading statements made during the Class Period from April 29, 2025, to June 22, 2025 [1][3] - Investors who acquired Hims & Hers securities during the Class Period have until August 25, 2025, to seek appointment as lead plaintiff representatives [1] Group 2: Partnership Termination - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive marketing practices and the sale of unapproved compounded versions of semaglutide [2] - Following the announcement, Hims & Hers shares dropped over 34% in intraday trading, indicating significant investor concern regarding regulatory compliance and reputational risks [2] Group 3: Allegations of Misleading Statements - The lawsuit alleges that Hims & Hers made materially false or misleading statements about the nature and regulatory status of its GLP-1 offerings and the risks associated with its partnership with Novo Nordisk [3] - The investigation is focused on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]. - Investors who acquired Fiserv securities between July 24, 2024, and July 22, 2025, can seek to be appointed as lead plaintiff representatives by the deadline of September 22, 2025 [2][5]. Group 2: Financial Impact - Fiserv's share price experienced a significant decline following disclosures on July 23, 2025, when the company lowered its 2025 organic growth projections and confirmed decelerated growth in its Merchant segment [4].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, with a class action lawsuit filed for investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2]. Group 1: Legal Action and Allegations - A class action lawsuit has been initiated on behalf of investors who purchased Petco securities during the specified Class Period [1][2]. - The complaint alleges that Petco made materially false and misleading statements regarding its pandemic-related advantages and the sustainability of its premium pet food business model [3]. - It is claimed that Petco overstated its ability to achieve profitable growth while downplaying operational challenges, leading to significant stock price declines, including a drop of over 20% on August 24, 2023, after a downward revision of financial guidance [3]. Group 2: Investor Information - Investors who acquired Petco securities during the Class Period have until August 29, 2025, to seek appointment as lead plaintiff representative of the class [2]. - For more information regarding the legal action, investors can contact Berger Montague [4][6].